abstract |
Disclosed is a controlled release dosage form comprising a therapeutically effective amount of a pharmaceutically active agent, which may be Acyclovir, that releases in about 12 hours 80-100% of the active agent in a simulated gastric juice in a first order rate of release in a USP type 2 dissolution test, and not containing a solubilizer or a swelling enhancer or both, containing (a) a tablet made from polymer matrix of at least two biocompatible polymers, which may be Carbopol 974P and polyethylene oxide, the pharmaceutically active agent and pharmaceutically permitted excipients; the tablet capable of rapid swelling without disintegration in the simulated gastric juice to a size that results in its gastric retention in the stomach and start controlled release of the active agent by starting controlled erosion as well as diffusion immediately after coming into contact with the gastric juice. |